NCT02971956View on ClinicalTrials.gov

Pembrolizumab in Refractory Advanced Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 18, 2017

Primary Completion Date

July 23, 2019

Study Completion Date

May 13, 2020

Conditions
Esophageal CancerSquamous Cell Esophagus CancerAdenocarcinoma Esophagus
Interventions
DRUG

Pembrolizumab

Immune checkpoint inhibitor

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02971956 - Pembrolizumab in Refractory Advanced Esophageal Cancer | Biotech Hunter | Biotech Hunter